Mainz Biomed Bv Stock Performance
| MYNZ Stock | USD 0.22 0.04 15.38% |
The company secures a Beta (Market Risk) of -0.47, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Mainz Biomed are expected to decrease at a much lower rate. During the bear market, Mainz Biomed is likely to outperform the market. At this point, Mainz Biomed BV has a negative expected return of -0.53%. Please make sure to verify Mainz Biomed's treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Mainz Biomed BV performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Mainz Biomed BV has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador | 09/18/2024 |
2 | The Covid Era Tech Promises To Reinvent Cancer Treatment | 10/01/2024 |
3 | Mainz Biomed Executes Convertible Note Agreement - TipRanks | 10/03/2024 |
4 | Personalized Treatment And Immunotherapy Are Pharmas Newest Weapons Against Cancer | 10/10/2024 |
5 | Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update | 10/21/2024 |
6 | The Oncology Bet Is Already Paying Off For Pfizer | 11/14/2024 |
7 | Mainz Biomed Shares Down 5.7 percent Heres What Happened | 11/21/2024 |
| Begin Period Cash Flow | 17.1 M | |
| Free Cash Flow | -23.8 M |
Mainz |
Mainz Biomed Relative Risk vs. Return Landscape
If you would invest 39.00 in Mainz Biomed BV on September 3, 2024 and sell it today you would lose (17.00) from holding Mainz Biomed BV or give up 43.59% of portfolio value over 90 days. Mainz Biomed BV is currently does not generate positive expected returns and assumes 8.7701% risk (volatility on return distribution) over the 90 days horizon. In different words, 78% of stocks are less volatile than Mainz, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mainz Biomed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mainz Biomed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mainz Biomed BV, and traders can use it to determine the average amount a Mainz Biomed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0606
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MYNZ |
Estimated Market Risk
| 8.77 actual daily | 78 78% of assets are less volatile |
Expected Return
| -0.53 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Mainz Biomed is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mainz Biomed by adding Mainz Biomed to a well-diversified portfolio.
Mainz Biomed Fundamentals Growth
Mainz Stock prices reflect investors' perceptions of the future prospects and financial health of Mainz Biomed, and Mainz Biomed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mainz Stock performance.
| Return On Equity | -43.34 | ||||
| Return On Asset | -0.99 | ||||
| Operating Margin | (18.83) % | ||||
| Current Valuation | 21.38 M | ||||
| Shares Outstanding | 64.04 M | ||||
| Price To Book | 1.72 X | ||||
| Price To Sales | 17.87 X | ||||
| Revenue | 895.48 K | ||||
| Gross Profit | 177.62 K | ||||
| EBITDA | (25.01 M) | ||||
| Net Income | (26.3 M) | ||||
| Cash And Equivalents | 26.01 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 7.42 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 10.83 X | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | (21.94 M) | ||||
| Earnings Per Share | (1.11) X | ||||
| Market Capitalization | 16.39 M | ||||
| Total Asset | 15.41 M | ||||
| Retained Earnings | (69.33 M) | ||||
| Working Capital | (257.15 K) | ||||
About Mainz Biomed Performance
Evaluating Mainz Biomed's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Mainz Biomed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mainz Biomed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 580.52 | 609.55 | |
| Return On Tangible Assets | (2.19) | (2.30) | |
| Return On Capital Employed | (4.32) | (4.10) | |
| Return On Assets | (1.71) | (1.79) | |
| Return On Equity | (8.09) | (7.69) |
Things to note about Mainz Biomed BV performance evaluation
Checking the ongoing alerts about Mainz Biomed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mainz Biomed BV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mainz Biomed BV generated a negative expected return over the last 90 days | |
| Mainz Biomed BV has high historical volatility and very poor performance | |
| Mainz Biomed BV has some characteristics of a very speculative penny stock | |
| Mainz Biomed BV has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 895.48 K. Net Loss for the year was (26.3 M) with profit before overhead, payroll, taxes, and interest of 177.62 K. | |
| Mainz Biomed BV currently holds about 26.01 M in cash with (21.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Mainz Biomed BV has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Mainz Biomed Shares Down 5.7 percent Heres What Happened |
- Analyzing Mainz Biomed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mainz Biomed's stock is overvalued or undervalued compared to its peers.
- Examining Mainz Biomed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mainz Biomed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mainz Biomed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mainz Biomed's stock. These opinions can provide insight into Mainz Biomed's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Mainz Stock Analysis
When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.